Achaogen (AKAO) Earns “Outperform” Rating from William Blair
William Blair reaffirmed their outperform rating on shares of Achaogen (NASDAQ:AKAO) in a research note released on Wednesday. William Blair also issued estimates for Achaogen’s Q1 2019 earnings at ($0.85) EPS, Q2 2019 earnings at ($0.81) EPS, Q3 2019 earnings at ($0.78) EPS and Q4 2019 earnings at ($0.74) EPS.
A number of other equities analysts also recently weighed in on AKAO. Mizuho reaffirmed a buy rating and set a $28.00 price target on shares of Achaogen in a research note on Thursday, November 9th. HC Wainwright reaffirmed a buy rating and set a $25.00 price target on shares of Achaogen in a research note on Thursday, November 9th. Stifel Nicolaus cut their price target on shares of Achaogen from $30.00 to $27.00 and set a buy rating on the stock in a research note on Thursday, November 9th. Zacks Investment Research downgraded shares of Achaogen from a hold rating to a sell rating in a research note on Tuesday, November 14th. Finally, ValuEngine raised shares of Achaogen from a sell rating to a hold rating in a research note on Sunday, December 31st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Achaogen presently has a consensus rating of Buy and an average price target of $24.10.
Achaogen (AKAO) opened at $10.48 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 4.83. The firm has a market cap of $455.59, a P/E ratio of -3.30 and a beta of 1.28. Achaogen has a one year low of $9.83 and a one year high of $27.79.
In other Achaogen news, major shareholder Robert W. Duggan acquired 527,396 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was bought at an average price of $10.31 per share, with a total value of $5,437,452.76. Following the completion of the transaction, the insider now directly owns 5,697,752 shares of the company’s stock, valued at $58,743,823.12. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kenneth J. Hillan sold 4,606 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $10.67, for a total transaction of $49,146.02. The disclosure for this sale can be found here. In the last three months, insiders bought 717,408 shares of company stock valued at $7,557,386 and sold 7,354 shares valued at $78,467. 8.36% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC acquired a new stake in Achaogen during the 4th quarter valued at $151,000. Clear Harbor Asset Management LLC acquired a new stake in Achaogen during the 4th quarter valued at $177,000. Ellington Management Group LLC acquired a new stake in Achaogen during the 4th quarter valued at $177,000. Tower Research Capital LLC TRC grew its holdings in Achaogen by 375.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock valued at $201,000 after purchasing an additional 14,725 shares in the last quarter. Finally, California Public Employees Retirement System acquired a new stake in Achaogen during the 2nd quarter valued at $243,000. 90.49% of the stock is owned by institutional investors.
WARNING: “Achaogen (AKAO) Earns “Outperform” Rating from William Blair” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/achaogen-akao-earns-outperform-rating-from-william-blair/1905854.html.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.